Sameh N Khouzam, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 4160 Little York Rd Ste 20, Dayton, OH 45414 Phone: 937-454-9527 Fax: 937-454-9532 |
Joel H Tobiansky, MD Internal Medicine - Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 1530 Needmore Rd, Ste 300, Dayton, OH 45414 Phone: 937-277-4274 Fax: 937-277-8476 |
Thomas G Thornton, MD Internal Medicine - Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 122 Wyoming St, Dayton, OH 45409 Phone: 937-223-4461 Fax: 937-224-1945 |
News Archive
Conclusive data show that hydroxyurea therapy offers safe and effective disease management of sickle cell anemia (SCA) and reduces the risk of stroke, prompting early termination by the National Heart Lung and Blood Institute of a key clinical trial studying the drug's efficacy.
New research at Columbia University Medical Center has revealed how special molecules help the tongue communicate with the brain to identify the correct taste.
A partnership among 20 European states, the European Union and a number of private enterprises has launched a three-year, 3.87-million-euro project to make robots capable of serving as adaptable, interactive, and above all safe assistants for elderly people. The research project, known as ALIAS, places special emphasis on maintaining social networks, warding off feelings of loneliness and isolation, and increasing activities that may protect and enhance cognitive capabilities.
More than 11,000 Americans die each year from skin cancer. Yet when detected early, skin cancer has a cure rate of 99 percent. That's why dermatologists from the American Academy of Dermatology's National Melanoma/Skin Cancer Screening Program conducted free skin cancer screenings at the Kentucky State Fair in Louisville, held Aug. 20-30, 2009.
Caraco Pharmaceutical Laboratories, Ltd. generated net sales of $97.8 million and $227.8 million during the second quarter ended September 30, 2010 and first six months of the Company's current fiscal year ended September 30, 2010, respectively, as compared to $78.4 million and $126.4 million, respectively, for the corresponding periods of the previous fiscal year ended September 30, 2009.
› Verified 9 days ago